Literature DB >> 15380577

Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma.

Vincent Moutardier1, Valérie Magnin, Olivier Turrini, Frédéric Viret, Stephanie Hennekinne-Mucci, Antony Gonçalves, Christian Pesenti, Jérome Guiramand, Bernard Lelong, Marc Giovannini, Geneviève Monges, Gilles Houvenaeghel, Jean-Robert Delpero.   

Abstract

PURPOSE: The benefits provided by preoperative chemoradiotherapy (CRT) in pancreatic ductular adenocarcinoma (PDA) are still controversial. However, in most reports from referral centers, improvement in local control and survival appears to be provided in selected patients. The aim of this retrospective study was to analyze the radiation-induced pathologic effects of preoperative CRT in patients with resectable PDA and determine the precise long-term outcome of the responding patients. METHODS AND MATERIALS: Between November 1996 and October 2003, 61 patients underwent preoperative CRT for resectable PDA. The tumor location was the pancreatic head in 49 patients and pancreatic body in 12 patients. Of the 61 patients, 21 (34.5%) did not undergo surgery because of disease progression and 40 (65.5%) underwent pancreatic resection, including pancreaticoduodenectomy in 32 (80%) and distal pancreatectomy in 8 (20%).
RESULTS: A major pathologic response was noted in 9 patients, including three complete responses, and was found only in patients with tumor of the pancreatic head. The local control rate was similar in patients with and without a major pathologic response. Survival in patients with a major response was significantly greater than in those without a response or with a minor response.
CONCLUSION: Major tumor downstaging can be provided by preoperative CRT in patients with resectable cephalic PDA. Survival appears to be significantly improved in selected patients.

Entities:  

Mesh:

Year:  2004        PMID: 15380577     DOI: 10.1016/j.ijrobp.2004.04.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.

Authors:  Sohei Satoi; Hideyoshi Toyokawa; Hiroaki Yanagimoto; Tomohisa Yamamoto; Minoru Kamata; Chisato Ohe; Noriko Sakaida; Yoshiko Uemura; Hiroaki Kitade; Noboru Tanigawa; Kentaro Inoue; Yoichi Matsui; A-Hon Kwon
Journal:  J Gastrointest Surg       Date:  2011-12-09       Impact factor: 3.452

Review 2.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

Review 3.  Neoadjuvant therapy for pancreatic cancer.

Authors:  Andrew M Lowy
Journal:  J Gastrointest Surg       Date:  2008-02-08       Impact factor: 3.452

Review 4.  Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?

Authors:  Thomas B Brunner
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

5.  Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Jeannelyn S Estrella; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Histopathology       Date:  2013-09-20       Impact factor: 5.087

Review 6.  The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma.

Authors:  Hiral D Parekh; Jason Starr; Thomas J George
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

7.  Assessment with cone-beam computed tomography of intrafractional motion and interfractional position changes of resectable and borderline resectable pancreatic tumours with implanted fiducial marker.

Authors:  Shingo Ohira; Masaru Isono; Yoshihiro Ueda; Takero Hirata; Reiko Ashida; Hidenori Takahashi; Masayoshi Miyazaki; Masaaki Takashina; Masahiko Koizumi; Teruki Teshima
Journal:  Br J Radiol       Date:  2017-03-03       Impact factor: 3.039

Review 8.  Adjuvant and neoadjuvant treatment in pancreatic cancer.

Authors:  Marta Herreros-Villanueva; Elizabeth Hijona; Angel Cosme; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2012-04-14       Impact factor: 5.742

9.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Gauri R Varadhachary; Robert A Wolff; Hua Wang; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Christopher Crane; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Cancer       Date:  2011-10-25       Impact factor: 6.860

Review 10.  TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Authors:  M Benavides; A Abad; I Ales; A Carrato; E Díaz Rubio; J Gallego; J García-Foncillas; C Grávalos; B Laquente; C Pericay; F Rivera; J Tabernero; E Aranda
Journal:  Clin Transl Oncol       Date:  2014-04-12       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.